Navigation Links
Biopure Exploring Strategic Options
Date:2/17/2009

Earnings for year ended October 31, 2008, contained in Annual Report filed on February 13, 2009, with Going Concern Modification

CAMBRIDGE, Mass., Feb. 17 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it is exploring strategic options for financing or alternative transactions. The company has engaged Newbury Piret & Co. to advise on options, including evaluation of nonbinding proposals that have been received. There should be no assumption that this process will result in any transaction or any particular type of transaction.

On February 13, 2009, the company filed with the SEC its Annual Report on Form 10-K, which contains the company's financial statements for the two years ended October 31, 2008. The company does not intend to issue a separate earnings release. The report of the company's independent registered public accounting firm contained in this filing is modified with respect to the company's ability to continue as a going concern.

Biopure Corporation

Biopure Corporation develops pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the company is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 214,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that any transaction will be entered into to prevent the company from ceasing operations. Actual results may differ materially from those in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, unexpected costs and expenses, the assessment of third parties of the Company's products and prospects, the Company's ability to negotiate a transaction with acceptable terms, and the other factors identified under the heading "Risk Factors" in the Company's annual report on Form 10-K filed on February 13, 2009, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. The company, for example, currently does not intend to provide updates regarding its exploration of strategic alternatives or to disclose developments or potential outcomes until and unless a definitive course of action is reached. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

    Contact:  Rob Skiba
              Biopure Corporation
              (617) 234-6500
              IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
2. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
3. Biopure Sues National Institutes of Health Official
4. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
5. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
6. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
7. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
8. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
9. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
10. Biopure Announces Closing of $14.9 Million Financing
11. Biopures Stock Symbol Reverts to BPUR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Dr. David Mahon ... Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson ... is an online directory that recognizes local physicians and dentists who have earned high ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research ... those in the fight against cancer, has produced a seminal study that asked ... will release top-line findings in a webinar, Defining Compassionate Care Through the Voices ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal ... program today with a new Indiegogo campaign . Individuals are now able ... in the Los Angeles area, either as a participating patient or through an Indiegogo ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Carlos ... problems. He has also continued to spiritually evolve, which is the purpose of everyone ... “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers to ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
(Date:2/23/2017)... Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company ... and market advanced products and therapies for the Wound ... sectors of healthcare, today announced its record results for ... 2016. Full Year 2016 Highlights are: ... full year 2015 revenue ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 9.2% over the next decade to reach approximately ... market estimates and forecasts for all the given segments on global ...
Breaking Medicine Technology: